IGM Biosciences (STU:1K0) Ending Cash Position : €25.46 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Ending Cash Position?

IGM Biosciences's Ending Cash Position for the quarter that ended in Dec. 2024 was €25.46 Mil.

IGM Biosciences's quarterly Ending Cash Position declined from Jun. 2024 (€62.49 Mil) to Sep. 2024 (€38.80 Mil) and declined from Sep. 2024 (€38.80 Mil) to Dec. 2024 (€25.46 Mil).

IGM Biosciences's annual Ending Cash Position declined from Dec. 2022 (€115.09 Mil) to Dec. 2023 (€103.72 Mil) and declined from Dec. 2023 (€103.72 Mil) to Dec. 2024 (€25.46 Mil).

IGM Biosciences Ending Cash Position Historical Data

The historical data trend for IGM Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Ending Cash Position Chart

IGM Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

198.17

118.62

115.09

103.72

25.46

IGM Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															103.72	73.14	62.49	38.80	25.46

IGM Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

IGM Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	108.021	+	-82.559
	=	25.46

IGM Biosciences's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	41.127	+	-15.665
	=	25.46

IGM Biosciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

IGM Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

IGMS:USA 1K0:Germany

Address

325 East Middlefield Road, Mountain View, CA, USA, 94043

Website

https://www.igmbio.com

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

IGM Biosciences Headlines

No Headlines